Document is current
Any future updates will be listed below
-
Authors
Kac, Przemysław R.
Cousins, Katheryn A. Q.
Szadziewska, Alicja
Shaw, Leslie M.
Turton, Michael
Van Deerlin, Vivianna M.
Harrison, Peter
Zetterberg, Henrik
Wolk, David A.
McMillan, Corey T.
Galasko, Douglas
Hanrieder, Jörg
Lee, Edward B.
Kvartsberg, Hlin
Irwin, David J.
Blennow, Kaj
-
Funding
Funding for this research was provided by:
Demensförbundet
Anna Lisa and Brother Björnsson’s Foundation
Stiftelsen för Gamla Tjänarinnor
Gun och Bertil Stohnes Stiftelse
Vetenskapsrådet (#2023-00356, #2022-01018 and #2019-02397)
Vetenskapsrådet (#2022-00732)
HORIZON EUROPE European Research Council (101053962)
Swedish State Support for Clinical Research (#ALFGBG-71320)
Alzheimer's Drug Discovery Foundation (#201809-2016862)
Alzheimer's Association ((#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C)
the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07)
the Bluefield Project
Cure Alzheimer’s Fund
the Olav Thon Foundation
the Erling-Persson Family Foundation
Familjen Rönströms Stiftelse
Hjärnfonden (#FO2022-0270)
Hjärnfonden (#FO2024-0048-TK-130 and FO2024-0048-HK-24)
the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie (No 860197 (MIRIADE))
EU Joint Programme – Neurodegenerative Disease Research (JPND2021-00694)
the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre
UK Dementia Research Institute (UKDRI-1003)
Anonymous donor
DeCrane Family foundation
Institute on Aging, University of Pennsylvania
National Institutes of Health (P01-AG-066597, P30-AG-072979, P01-AG084497, R01-AG087258, R01AG090414, R01-NS109260)
Swedish Alzheimer Foundation (#AF-994551)
Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-1006418)
University of Gothenburg
- License Information
-
More Information
Article History
Received: 13 October 2025
Revised: 4 June 2026
Accepted: 10 June 2026
First Online: 24 June 2026
Declarations
:
: MT and PH are employees of Bioventix Plc. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, Roche, and WebMD, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). PRK received royalties from Bioventix Plc (outside submitted work). KB has during 2023–2025 served as a consultant, at advisory boards, and has given lectures, produced educational materials and participated in educational programs for AC Immune, ALZPath, AriBio, Beckman-Coulter, BioArctic, Eisai, Lilly, Neurimmune, Novartis, Roche Diagnostics, Sunbird Bio, and Siemens Healthineers; all before Sept 2025, and is since Sept 2025 an employee of Lilly. KB is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. DJI receives research funding paid to the institution for clinical trials by Alector, Cervo Med, Denali, Passage Bio and Prevail. DJI has unpaid positions on the scientific advisory board for the LBDA, the medical advisory board for the Association for Frontotemporal Degeneration and the board of directors for the International Society for Frontotemporal Dementias. EBL received consulting fees from Eli Lilly. The other authors declare no competing interest.
